Category: 3. Business

  • Benefits of Net 30/60/90 Terms

    Benefits of Net 30/60/90 Terms

    The net terms on invoices your company receives aren’t just payment deadlines—they directly impact your working capital and vendor relationships.

    Paul Kizirian, Executive Director for Treasury Consulting at J.P. Morgan, explains how invoice payment terms work, why accounts payable (AP) automation is key to capturing early payment discounts and shares strategies for optimizing working capital while meeting terms.

    Net terms represent the payment timeline within trade credit agreements between vendors and buyers.

    They’re commonly expressed as net 30, net 60 or net 90, and give buyers 30, 60 or 90 days, respectively, to submit payment for the net—or full—amount invoiced.

    While net 30 is a particularly common invoice payment term, vendors and buyers tailor terms to their operational and cash flow needs.

    A vendor that wants to incentivize faster payment may offer an early payment discount. For example, 2/10 net 30 means the buyer receives a 2% discount if they pay within 10 days. Otherwise, the full amount is due in 30 days. The buyer can’t claim the discount if they are slow to process invoices and cannot pay within the 10-day time frame.

    Invoice payment terms influence working capital and supplier relationship management.

    Shifting from net 30 to net 60 lets buyers hold cash twice as long, extending Days Payable Outstanding (DPO), which provides a direct working capital benefit. But it has the opposite effect on vendors by delaying their receivables, extending their Days Sales Outstanding (DSO). Vendors prefer to minimize DSO within their accounts receivable.

    Negotiating terms should include discussing early payment discounts as a strategy that helps buyers and vendors balance their working capital needs.

    “If the buyer can consistently capture discounts, the bottom-line savings can be significant. Terms are very important yet often overlooked,” Kizirian said.

    Continue Reading

  • US labor costs growth moderates in third quarter – Reuters

    1. US labor costs growth moderates in third quarter  Reuters
    2. Q3 ECI: Cooling compensation growth a sign of jobs market softening  FXStreet
    3. Worker pay and benefits rise faster than inflation — but that gap is shrinking in a poorer jobs market  MarketWatch
    4. U.S. labor cost growth drops to 3.5%, easing inflationary pressures  Bitget
    5. Wage Growth Slows in Positive Sign for Inflation  Barron’s

    Continue Reading

  • Fed meeting live: Stock markets await rate cut decision, 2026 projections in focus – Reuters

    1. Fed meeting live: Stock markets await rate cut decision, 2026 projections in focus  Reuters
    2. Citadel Securities’ Rubner Bullish Into Year-End, Early 2026  Bloomberg.com
    3. Bull market will continue run in 2026, will be bumps in the road: Hennion & Walsh’s Kevin Mahn  MSN
    4. ‘The North Star for the Bull Market Is Still Corporate Profits’: 2026 Stock Market Expectations  Kiplinger
    5. Bullish Case Or Bearish Backdrop  Real Investment Advice

    Continue Reading

  • SEC Chief Accountant Unveils Ambitious Agenda for Audit Oversight, Standard Setting

    At a year-end AICPA conference, Securities and Exchange Commission (SEC) Chief Accountant Kurt Hohl outlined an ambitious agenda for accounting and auditing for the coming years, including active oversight of the Public Company Accounting Oversight Board (PCAOB) and the Financial Accounting Standards Board (FASB).

    Most notably, the profession can expect changes to the way the PCAOB inspects public company audits and how the board sets standards. If implemented, these changes will represent major shifts in the supervision of auditors.

    Such planned efforts come as President Trump’s SEC chair appointee, Paul Atkins, has emphasized the capital formation aspect of the agency’s mission. By contrast, the previous leadership during the Biden administration focused on aggressive rulemaking and enforcement priorities.

    Hohl said that his agenda largely stems from changes in the business environment.

    PCAOB Audit Inspections

    The accounting chief said that the inspection process has largely worked the same way for the last two decades. The Sarbanes-Oxley Act of 2002 established the PCAOB following accounting scandals at companies like Enron and WorldCom, and board inspections have helped to improve audit quality over the years.

    “There’s a change in standards that basically maybe requires the PCAOB to change how they focus on inspecting firms,” Hohl said, referring to the quality management standards adopted by the International Auditing and Assurance Standards Board (IAASB) in 2020 which became effective in 2022. In particular, Hohl pointed to IAASB Quality Management Standards (ISQM) 1.

    The AICPA’s Auditing Standards Board, which writes auditing standards for private companies, adopted its own quality management standards based on ISQM 1. The AICPA’s goal is to converge with international standards as much as possible.

    “So all auditors in the U.S. are essentially following ISQM 1 or some derivation that’s fairly close,” he said.

    For public companies in the U.S., the PCAOB last year adopted Quality Control 1000, and firms are preparing to implement the new standard, though the effective date got delayed by one year.

    “Maybe there’s an opportunity for the PCAOB to shift the inspection program to focus more on system of quality management. And I think what that will do, in my own personal view, is it will shift the accountability to the leadership of the firm and their systems and processes, and less on individual engagement teams and the partners,” Hohl said at the AICPA Conference on Current SEC and PCAOB Developments in Washington on December 8, 2025.

    “There’s a lot of stress in the environment for teams who get inspected,” Hohl explained. “So a shift in focus toward the firm and how they support their engagement teams and the execution of high-quality audits, I think, is probably overdue.”

    Moreover, Hohl will look at refreshing the PCAOB’s audit inspection reports.

    During his roughly five months as chief accountant, Hohl has reached out to various stakeholders, including audit committee members, to try to better understand how they use inspection reports.

    “Is it really a useful mechanism for communicating audit quality outside the firms. And I think there’s a lot of room if you’re going to change the inspection process to focus more on system of quality management that has complications for how the inspection report might read, because there’s a provision in the statute that keeps quality control findings kind of private for a year unless the firms remediate,” Hohl said. “So there’s a lot of opportunity [to add] some contextual information to inspection reports.”

    PCAOB Standard-Setting Process

    Hohl said that the PCAOB could do something similar to what the accounting standard setter FASB does when it routinely conducts public agenda consultations, asking stakeholders which projects it should work on.

    “I think the PCAOB could benefit from that as well,” he said.

    In another major shift, Hohl believes that the PCAOB, just as the AICPA is doing, should try to converge with IAASB standards as much as possible, especially as all the major firms use the international auditing standards as the baseline for their audit.

    In his view, it will “be beneficial for investors because it will essentially develop a single set of high-quality standards. It will essentially significantly reduce cost and complexity, because if you’re working on a multinational group audit and you’re doing statutory accounts in your local under ISA standards, and you basically are working on as a component for an SEC engagement, you have to basically use a different set of standards, and that adds confusion, costs, and the risk for non-compliance.”

    PCAOB Consultation

    Just as the SEC’s Office of Chief Accountant (OCA) provides consultation on tricky accounting matters to preparers and auditors before filing financial statements, Hohl said the PCAOB staff can provide consultation on difficult audit issues.

    “I think auditors struggle with the same thing: ‘How do I basically apply the auditing standards in a fact pattern that I’m dealing with and try to get answers from the PCAOB staff that they basically can apply before they finish their audit,’ so that they don’t get an inspection finding someplace down the road,” Hohl said.

    Auditor Reporting

    Auditors provide a lot of disclosures either to the PCAOB or the audit committees. “I would basically like to readjust that to focus on really material items that are relevant to investors,” he said.

    Waiting for New Board Members

    In the meantime, the first order of business is for the SEC to appoint PCAOB members in the coming weeks. The SEC will replace all or almost all current board members. Board member Christina Ho said she is not seeking her second term. One current member might be kept on for continuity. For example, in prior appointment in late 2021, the SEC replaced all except for Duane DesParte, who briefly served as acting chair and subsequently left when his term ended in October 2023. Thus, it remains to be seen if Acting PCAOB Chair George Botic will go back to being a board member for continuity. Botic succeeded DesParte.

    FASB Oversight

    Hohl said he regularly talks with FASB Chairman Rich Jones, and he is focused on the timeliness of standard-setting.

    The OCA staff has held off on all the crypto issues until Hohl came to the SEC.

    “The challenge with that is they don’t fit really neatly into existing accounting standards. So trying to get issues accumulated and talk to the FASB and see whether they can have some mechanism like the reconstituted EITF [emerging issues task force] to take some of these issues up is really important,” he said. “Obviously, our offices can answer these questions, and we have the authority to interpret what the accounting standards are, but I’m very appreciative of the due process, and making sure that we’re careful and thoughtful about how accounting standards are developed and making sure that we work closely with the FASB is a critical element of that.”

    Hohl and Jones have started to discuss these crypto issues and will decide whether some of these could be put on the EITF agenda or whether the SEC or FASB should provide guidance in another way.

    Cost-Benefit of Standards

    The SEC’s top accountant said that he is also “extremely focused on” cost and benefit analysis, which is a major challenge.

    “Standard setting is a very difficult task, and you’re trying to basically please the two factions on opposite sides: investors want more information; preparers who are basically focused on compliance costs associated with those new standards,” Hohl said.

    Thus, he asked Jones and his team to make sure that the FASB engages in a thoughtful manner to figure out the costs of new disclosure standards because high compliance costs discourage companies from accessing the public market.

    Convergence With International Accounting Standards

    In terms of accounting convergence, Hohl told Jones that it is important for him to work with the International Accounting Standards Board (IASB) in developing international accounting standards and vice versa for the IASB to work with the FASB to learn from each other.

    Hohl is focused on getting as much cooperation and convergence as possible as it will reduce investor confusion.

    “There’s new costs associated with it. And I think we can basically leverage the work of each body to get developing standards out faster,” Hohl said. “So if the IASB takes a topic first, and the FASB wants to basically take a similar project afterward, they can basically learn from the feedback that that the IASB has gotten, and they think maybe get out standards on a quicker basis. The big challenge here, too, on the cost side, is trying to figure out how to get preparers and those types of stakeholders participating in the standard setting process.”

    Auditors, especially big firms and investors voice their views. But some trade associations for preparers come after the fact and tell the FASB that they don’t like the standard and ask the board to change it or ask if they do not have to follow it.

    “And we have to figure out a mechanism for companies to participate on the front side of the project to inform the FASB so that we can get fairly high-quality standards at a reasonable cost,” he said.

    Auditor Independence Rule Review

    The OCA will also review audit firm independence rules as private equity firms are increasingly investing in accounting firms, and both companies and firms are using artificial intelligence (AI) to save money or make various functions more effective and efficient.

    Alternative practice structures provide a capital boost to invest in emerging technologies, but they also present risks, especially in the independence of auditors.

    “So we’ll be focused on those emerging issues as they develop and decide and figure out what we need to do,” Hohl said.

     

    Take your tax and accounting research to the next level with Checkpoint Edge and CoCounsel. Get instant access to AI-assisted research, expert-approved answers, and cutting-edge tools like Advisory Maps and State Charts. Try it today and transform the way you work! Subscribe now and discover a smarter way to find answers.

    Continue Reading

  • Improved Cardiac Remodeling Following TTVR, TTVA

    Improved Cardiac Remodeling Following TTVR, TTVA

    Two recent studies published in JACC: Cardiovascular Interventions focus on improved cardiac remodeling following transcatheter valve replacement (TTVR) and transcatheter valve annuloplasty (TTVA).

    The first, a single-center, retrospective, shorter-term TTVR study conducted by Robin Le Ruz, MD, Rebecca T. Hahn, MD, FACC, et al., analyzed 80 TTVR patients (median age, 81; 65% women), 88% of whom had baseline massive/torrential tricuspid regurgitation (TR). The replacements (80% used the EVOQUE system) were a technical success in 90% of patients, and 96% presented with only mild or less TR post implantation.

    Results at a median follow up of 40 days showed that TTVR was associated with a reduction in right ventricular (RV) end diastolic volume (EDV; 138.2 mL/m2 to 59.5 mL/m2; p<0.001) and increase in septal curvature and stroke volume, leading to a 65% increase in effective RVEF and 20% increase in RV coupling.

    Additionally, this reduction in RVEDV was reciprocal with an increase in left ventricular (LV) EDV (49.6 mL/m2 to 57.9 mL/m2; p=0.001). Greater discordance of these two volumes at baseline, as indicated by an average eccentricity index (aEI) ≥1.25, led to greater reverse remodeling, lower follow-up NT pro-BNP levels and greater symptom improvement.

    On the eccentricity index, the study authors write, “Our findings add to the growing literature supporting the use of multi-modality imaging to defining subpopulations of patients that may derive greater benefit from TTVR and by which shared decision-making about device choice could be made.”

    In an accompanying editorial comment, Muhammed Gerçek, MD, and Felix Rudolph, MD, add that “Incorporating such imaging biomarkers into next-generation risk models could refine patient selection and predict tolerance to sudden afterload shifts.”

    The second, longer-term TTVA study, by Caroline Hasse, MD, et al., followed 156 patients (median age, 79 years; 76% women; 89% with atrial fibrillation) undergoing TTVA for severe TR (27% with massive and 42% with torrential) using the Cardioband system. The procedure was successful in 62% of patients, and 37% still had severe or greater TR at discharge.

    Results at a median follow-up of 435 days showed that 71% of patients had a TR reduction ≤2+, and 68% improved in NYHA functional class ≤III (p<0.001 for both) following TTVA. Compared with baseline, right atrial area (36.0 vs. 30.4 cm2), RV length (67.5 vs. 63.7 mm), RV midventricular dimension (42.6 vs. 35.6 mm) and RV basal dimension (47.8 vs. 42.6 mm) were all significantly reduced at follow-up (p<0.001 for all).

    JACC Central Illustration: Long-Term Outcomes After Transcatheter Direct Annuloplasty of Secondary TR

    Torrential to severe TR reduction still led to remodeling (RV basal diameter, 50 vs. 44 mm; p=0.007) and additionally, right heart remodeling was associated with a decrease in vena contracta width (odds ratio, 1.14; p=0.015).

    Hasse, et al., note that in the study, residual TR ≥3 at discharge was associated with an elevated mortality rate compared with TR <3 (26% vs. 13%; p=0.042). “Residual TR therefore must be taken seriously. Close clinical follow-up and the evaluation of further treatment options, such as staged edge-to-edge repair, should be carefully taken into consideration in this vulnerable ‘high-risk-cohort,’” they write.

    While “the investigators should be commended for assembling a large cohort of patients treated with a single device and for providing a comprehensive clinical and echocardiographic evaluation,” write David Messika-Zeitoun, MD, PhD; Maurice Enriquez-Sarano, MD, FACC; and Julien Dreyfus, MD, PhD, in an accompanying editorial comment, they add that in addition to residual TR severity – procedural complexity, patient selection and timing of intervention all remain crucial concerns for future work.

    • Le Ruz, R, Agarwal, V, George, I. et al. Cardiac Remodeling After Transcatheter Tricuspid Valve Replacement: Insights From Multimodality Imaging. J Am Coll Cardiol Intv. Published online, November 26, 2025. doi:10.1016/j.jcin.2025.10.023
    • Hasse, C, von Stein, P, Althoff, J. et al. Cardiac Remodeling Following Transcatheter Tricuspid Valve Annuloplasty for Tricuspid Regurgitation: A Real-World, Multicenter Analysis. J Am Coll Cardiol Intv. 2025 (23)2911-2921. doi:10.1016/j.jcin.2025.10.010

    Continue Reading

  • Lenovo Paves the Way for AI Innovation with Modern Data Storage Solutions and Services

    Lenovo Paves the Way for AI Innovation with Modern Data Storage Solutions and Services

    • New Lenovo ThinkSystem and ThinkAgile storage and virtualization infrastructure solutions provide optimal performance, security and efficiency for the most demanding AI and enterprise workloads  
    • New Lenovo ThinkSystem DS Series Storage Arrays provide simple deployment and management for virtualized environments running mission-critical enterprise workloads 
    • New Lenovo ThinkAgile FX Series provides maximum flexibility and investment protection with a multi-vendor hyperconverged infrastructure (HCI) appliance.  
    • Tailored Lenovo Hybrid Cloud Advisory and Deployment services leverage structured and unstructured data to achieve business outcomes with AI 

    December 10, 2025 – Lenovo today announced an expansive series of new data storage, virtualization solutions and data management services, designed to help customers modernize their IT and data infrastructure for powering enterprise applications and AI ready capabilities. Today’s new offerings include new Lenovo ThinkSystem and ThinkAgile data storage and virtualization solutions, announced in tandem with data management services. Designed to provide a modern foundation for enterprises and mid-size businesses achieving AI innovations, this announcement combines complementary hardware, software and services offerings to help deploy, manage, and unleash the true potential of enterprise data. 

    “Sixty-three percent of organizations either do not have or are unsure if they have the right data management practices for AI, according to a survey by Gartner ®.” 1  Customer unique data is the differentiation that will drive their competitive advantage and most accurate results, however 80% of storage deployed in the last 5 years is on slower hard drive-based storage (according to IDC reporting) that is not optimized for AI. At the same time, customers are challenged with new virtualization and containerization requirements that demand open solutions. Businesses must mitigate this risk by ensuring their enterprise data systems and practices are modernized for advanced use cases. 

     “With disruptions in enterprise virtualization strategies and the mandate to make their data ready for the most demanding workloads, organizations are looking to modernize their legacy infrastructure with open solutions,” said Stuart McRae, Executive Director and General Manager of Data Storage at Lenovo. “These new offerings provide the security, flexibility, and performance to optimize enterprise applications and power enterprises to extract maximum value from data.” 

    Flexibility and Choice for Virtualization and Data Needs 

    Businesses today need the efficiency and cyber resiliency of their systems to run parallel to performance, simplicity, and scalability with an option to deploy on-prem and hybrid so that the data can stay in place for compliance while AI workloads run where appropriate. Lenovo has introduced new Lenovo ThinkSystem and Lenovo ThinkAgile Enterprise offerings optimized or AI, virtualization and storage bottlenecks, including: 

    • Lenovo ThinkSystem DS Series Storage Arrays: All-flash and protected Storage Area Network (SAN) block storage systems that are simple to deploy and manage for virtualized environments, improving performance and efficiency for virtualization and data modernization. 
    • Lenovo ThinkAgile FX Series: Hyperconverged Infrastructure (HCI) that delivers an open architecture that supports seamless conversion between select HCI solutions without replacing hardware, delivering maximum investment protection and flexibility.   
    • Lenovo ThinkAgile MX Series for disaggregated storage for Microsoft Azure Local: As a hyperconverged infrastructure (HCI) integrated appliance provider with Microsoft, we are expanding support for disaggregated external Fibre Channel Storage Area Networks (SAN to deliver greater enterprise storage support for virtualization customers. 
    • Lenovo ThinkAgile MX Series with NVIDIA RTX Pro 6000:   Integrated next generation GPU support to power advanced AI performance capabilities for enterprise inferencing with Microsoft Azure Local. 
    • Lenovo ThinkAgile HX Series for AI Lenovo’s HCI offering features Nutanix Enterprise AI (NAI) software stack to enable customers running in virtualized and distributed containerized environments to deploy, run, and scale AI models in minutes. 

    Complete Lifecycle Services Optimized for Advanced Workloads including AI  

    To help customers fully realize the benefits of their new systems and prepare their data for AI, Lenovo is extending this momentum with a broad portfolio of hybrid cloud and data lifecycle services designed to modernize environments, strengthen reliability, and support evolving storage and AI workload requirements. This portfolio includes Lenovo Deployment Services for ThinkAgile and ThinkSystem that help organizations accelerate time to value through more efficient infrastructure rollout, alongside a range of storage services that can be consumed individually or through Lenovo’s flexible TruScale model to enhance performance, agility, and innovation across the data storage lifecycle. 

    To guide long-term strategy, Lenovo’s Hybrid Cloud Advisory Services help customers align on-prem or hybrid environments with compliance, data protection, and operational efficiency. Lenovo’s Migration Services help organizations optimize data and workloads by combining cloud flexibility with the dependability of existing infrastructure. 

    As part of Lenovo’s expanded Data Management Services portfolio, Lenovo Premier Enhanced Storage Support delivers a specialized, storage-focused experience for IT teams managing critical workloads. With direct access to Lenovo experts, customers benefit from proactive monitoring, performance optimization, and guided issue resolution—helping ensure systems run reliably, are better protected, and maintain the resilience needed to support AI innovation and hybrid cloud growth. 

    Explore how Lenovo is powering the future of Enterprise AI and Storage at https://www.lenovo.com/datastoragesolutions. 

     

    About Lenovo 

    Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. 

     

    LENOVO, THINKSYSTEM, THINKAGILE AND TRUSCALE are trademarks of Lenovo. NVIDIA and RTX are trademarks of NVIDIA Corporation, Inc. All other trademarks are the property of their respective owners. ©2025 Lenovo Group Limited. All rights reserved. 

    Continue Reading

  • Consumer test drive: can AI do your Christmas gift shopping for you? | Shopping

    Consumer test drive: can AI do your Christmas gift shopping for you? | Shopping

    The question “what present do you recommend for …” will be tapped into phones and computers countless times over this festive period, as more people turn to AI platforms to help choose gifts for loved ones.

    With a quarter of Britons using AI to find products, brands are increasingly adapting their strategies to ensure their products are the ones recommended, especially those trying to reach younger audiences.

    But can AI offer thoughtful, personal suggestions for friends and family? The Guardian put the idea to the test.

    First we tried asking for possible gifts for a middle-aged man who enjoys running and photography. The market-leading chatbot ChatGPT suggested: a Canon lens for £129 from Argos; a Koospur tennis racket sensor tracker for £71.72 on Amazon; and a Boondocker recycled camera bag for £34.98. The AI platform insisted the “ideal present” would be the camera bag, plus maybe the tennis sensor tracker. It also threw in experience ideas such as tennis coaching, whisky tasting or live music.

    When asked to work with a more restricted budget it suggested tennis racket-emblazoned socks for £18, which were ugly and definitely not worth the high price tag.

    The answers skewed heavily towards big online retailers, with seven of the nine initial suggestions from Amazon. Asking for ideas from more niche companies led to a minimalist tennis court print for £30 from a website called the Smart Party Shop and vague advice to buy from “Etsy or Not On the High Street-type sellers”.

    Searching for a woman who likes beauty products, DIY and fitness again produced some middle-of-the-road suggestions. However, with a nudge for more cult picks it steered towards a £17.50 Odylique rose moisturiser gift set, which it described as “luxurious but not mainstream”. It also put forward a £30 Floris sandalwood and patchouli-scented candle, which it claimed was “more personal than just another lipstick”.

    When asked to recommend DIY tools, it suggested a small, pink kit with some rather useless-looking pliers, rather than the usual all-purpose devices such as drills, sanders and staple guns – a sign that the longstanding complaint that AI reinforces gender stereotypes remains.

    The Guardian then instructed the AI to try shopping locally, using the example of homeware ideas in south London. ChatGPT said to try ALKEMI, an independent lifestyle store in Nunhead. When the area was narrowed down to Herne Hill it suggested two shops: Jo’s House and Forget Me Not And Green.

    skip past newsletter promotion

    Trying other AI models did not appear to vary the quality of responses much. Searching on Google’s Gemini for gifts for a man who likes chess, video games, reading and music, specifically techno and house threw up these top suggestions: a book on chess strategy for £22; a £50 Bandcamp gift card; or a hot sauce tasting kit for about £30-£40.

    So what were the main takeaways from the exercise? AI seems to favour bigger brands (especially Amazon) unless you tell it not to. It can find you a gift, just not necessarily one that says anything more than “an algorithm picked this”. Perhaps you’ll have a bit more luck if you are willing to spend the time to steer it towards more relevant answers, but then it sort of defeats the point.

    Continue Reading

  • From early cars to generative AI, new technologies create demand for specialized materials

    From early cars to generative AI, new technologies create demand for specialized materials

    Generative artificial intelligence has become widely accepted as a tool that increases productivity. Yet the technology is far from mature. Large language models advance rapidly from one generation to the next, and experts can only speculate how AI will affect the workforce and peoples’ daily lives.

    As a materials scientist, I am interested in how materials and the technologies that derive from them affect society. AI is one example of a technology driving global change – particularly through its demand for materials and rare minerals.

    But before AI evolved to its current level, two other technologies exemplified the process created by the demand for specialized materials: cars and smartphones.

    Often, the mass adoption of a new invention changes human behavior, which leads to new technologies and infrastructures reliant upon the invention. In turn, these new technologies and infrastructures require new or improved materials – and these often contain critical minerals: those minerals that are both essential to the technology and strain the supply chain.

    The unequal distribution of these minerals gives leverage to the nations that produce them. The resulting power shifts strain geopolitical relations and drive the search for new mineral sources. New technology nurtures the mining industry.

    The car and the development of suburbs

    At the beginning of the 20th century, only 5 out of 1,000 people owned a car, with annual production around a few thousand. Workers commuted on foot or by tram. Within a two-mile radius, many people had all they needed: from groceries to hardware, from school to church, and from shoemakers to doctors.

    Then in 1913, Henry Ford transformed the industry by inventing the assembly line. Now, a middle class family could afford a car: Mass production cut the price of the Model T from US$850 in 1908 to $360 in 1916. While the Great Depression dampened the broad adoption of the car, sales began to increase again after the end of World War II.

    Henry Ford at wheel, with John Burroughs and Thomas Edison in back seat of a Model T.
    Bettmann/Contributor via Getty Images

    With cars came more mobility, and many people moved farther away from work. In the 1940s and 1950s, a powerful highway lobby that included oil, automobile and construction interests promoted federal highway and transportation policies, which increased automobile dependence. These policies helped change the landscape: Houses were spaced farther apart, and located farther away from the urban centers where many people worked. By the 1960s, two-thirds of American workers commuted by car, and the average commute had increased to 10 miles.

    Public policy and investment favored suburbs, which meant less investment in city centers. The resulting decay made living in downtown areas of many cities undesirable and triggered urban renewal projects.

    An overhead shot of a neighborhood made up of neat lines of houses and roads.
    Access to cars led to more spread-out neighborhoods, like this one in Milton, Ontario.
    SimonP/Wikimedia Commons, CC BY-SA

    Long commutes added to pollution and expenses, which created a demand for lighter, more fuel-efficient cars. But building these required better materials.

    In 1970, the entire frame and body of a car was made from one steel type, but by 2017, 10 different, highly specialized steels constituted a vehicle’s light-weight form. Each steel contains different chemical elements, such as molybdenum and vanadium, which are mined only in a few countries.

    While the car supply chain was mostly domestic until the 1970s, the car industry today relies heavily on imports. This dependence has created tension with international trade partners, as reflected by higher tariffs on steel.

    The cell phone and American life

    The cell phone presents another example of a technology creating a demand for minerals and affecting foreign policy. In 1983, Motorola released the DynaTAC, the first commercial cellular phone. It was heavy, expensive and its battery lasted for only half an hour, so few people had one. Then in 1996, Motorola introduced the flip phone, which was cheaper, lighter and more convenient to use. The flip phone initiated the mass-adoption of cell phones. However, it was still just a phone: Unlike today’s smartphones, all it did was send and receive calls and texts.

    A large, clunky phone.
    The Motorola DynaTAC 8000X was the first commercially available cellphone. With innovations and better materials, cellphones later became smaller, more lightweight and adopted touch screens.
    Redrum0486/Wikimedia Commons, CC BY-SA

    In 2007, Apple redefined communication with the iPhone, inventing the touch screen and integrating an internet navigator. The phone became a digital hub for navigating, finding information and building an online social identity. Before smartphones, mobile phones supplemented daily life. Now, they structure it.

    In 2000, fewer than half of American adults owned a cellphone, and nearly all who did it only sporadically. In 2024, 98% of Americans over the age of 18 reported owning a cellphone, and over 90% owned a smartphone.

    Without the smartphone, most people cannot fulfill their daily tasks. Many individuals now experience nomophobia: They feel anxious without a cellphone.

    Around three quarters of all stable elements are represented in the components of each smartphone. These elements are necessary for highly specialized materials that enable touch screens, displays, batteries, speakers, microphones and cameras. Many of these elements are essential for at least one function and have an unreliable supply chain, which makes them critical.

    An infographic showing the elements used in each component of a smartphone
    Smartphones contain around 80% of all known stable chemical elements, including some rare earth metals.
    Andy Brunning/Compound Interest 2023, CC BY-NC-ND

    Critical materials and AI

    Critical materials give leverage to countries that have a monopoly in mining and processing them. For example, China has gained increased power through its monopoly on rare earth elements. In April 2025, in response to U.S. tariffs, China stopped exporting rare earth magnets, which are used in cellphones. The geopolitical tensions that resulted demonstrate the power embodied in the control over critical minerals.

    Six small piles of minerals.
    Piles of rare earth oxides praseodymium, cerium, lanthanum, neodymium, samarium and gadolinium.
    Peggy Greb/USDA-ARS

    The mass adoption of AI technology will likely change human behavior and bring forth new technologies, industries and infrastructure on which the U.S. economy will depend. All of these technologies will require more optimized and specialized materials and create new material dependencies.

    By exacerbating material dependencies, AI could affect geopolitical relations and reorganize global power.

    America has rich deposits of many important minerals, but extraction of these minerals comes with challenges. Factors including slow and costly permitting, public opposition, environmental concerns, high investment costs and an inadequate workforce all can prevent mining companies from accessing these resources. The mass adoption of AI is already adding pressure to overcome these factors and increase responsible domestic mining.

    While the path from innovation to material dependence spanned a century for cars and a couple of decades for cell phones, the rapid advancement of large language models suggests that the scale will be measured in years for AI. The heat is already on.

    Continue Reading

  • Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers

    SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III ASCENT-07 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

    “HR-positive, HER2-negative breast cancers are typically treated with first-line endocrine therapy, but treatment resistance is common,” said Komal Jhaveri, MD, the Patricia and James Cayne chair for junior faculty; associate attending, Breast Medicine and Early Drug Development Services; and section head of the Endocrine Therapy Research Program at Memorial Sloan Kettering Cancer Center.

    “In cases where HR-positive, HER2-negative, metastatic breast cancer has become refractory to endocrine therapy, chemotherapy remains a common standard,” she explained. “Chemotherapy agents have shown marginal survival benefit but are associated with numerous toxicities that can be severe and long-lasting. Therefore, there remains a high unmet need in this setting for additional effective treatments.”

    Sacituzumab govitecan-hziy is an antibody-drug conjugate that targets the TROP-2 protein found on the surface of most breast cancer cells to deliver a cytotoxic agent to these cells, as well as to neighboring cells within the tumor microenvironment. One of the therapeutic’s approved indications is for patients with HR-positive, HER2-negative advanced breast cancers that have progressed on or after endocrine therapy and chemotherapy. The approval was based on statistically significant and clinically meaningful PFS and overall survival (OS) data from the phase III TROPiCS-02 clinical trial, said Jhaveri. In that study, patients treated with sacituzumab govitecan-hziy after two or more lines of chemotherapy had a 34% lower risk of disease progression or death and a 3.2-month improvement in OS compared with those treated with another line of chemotherapy.

    Those results led Jhaveri and colleagues to ask whether sacituzumab govitecan-hziy would also be beneficial earlier in the treatment course—for patients who had received endocrine therapy but who had not yet been treated with chemotherapy.

    To test this, they conducted the ASCENT-07 trial, which enrolled 690 patients with HR-positive, HER2-negative advanced breast cancers who had received prior endocrine therapy and who were candidates for first chemotherapy. Patients were randomly assigned (2:1) to receive either sacituzumab govitecan-hziy or standard-of-care chemotherapy.

    The ASCENT-07 trial did not meet its primary endpoint of improved PFS by blinded independent central review. After a median follow-up of 15.4 months, the median PFS was 8.3 months in both arms with a hazard ratio of 0.85.

    While data on OS were not mature at the time of this primary analysis, Jhaveri noted that preliminary results suggest a potentially lower risk of death among patients treated with sacituzumab govitecan-hziy. “It will be critical that we continue to follow patients for overall survival to better understand the potential long-term impact of sacituzumab govitecan-hziy in this treatment setting,” she added.

    The rates of treatment response were similar between the arms, but numerically higher for patients treated with sacituzumab govitecan-hziy, with 37% of patients experiencing responses to sacituzumab govitecan-hziy and 33% to chemotherapy. The median duration of response was numerically longer with sacituzumab govitecan-hziy than with chemotherapy (12.1 months vs. 9.3 months).  

    According to Jhaveri, the toxicities associated with sacituzumab govitecan-hziy in this trial were consistent with those observed in previous breast cancer studies. In both arms, the most common grade 3 or higher treatment-related adverse events were neutropenia and leukopenia, with both of these occurring at higher rates among patients treated with sacituzumab govitecan-hziy. Treatment-related adverse events that led to treatment discontinuation were observed in approximately 3% of patients in the sacituzumab govitecan-hziy and 7% in the chemotherapy arm.

    “While our study did not meet its primary endpoint of PFS for patients who have not yet received chemotherapy, sacituzumab govitecan-hziy remains a standard of care for HR-positive, HER2-negative metastatic breast cancers after prior endocrine therapy and chemotherapy based on the PFS and overall survival results seen in the TROPiCS-02 study,” said Jhaveri.

    “HR-positive, HER2-negative metastatic breast cancer is a highly heterogeneous disease, and this complexity makes it particularly challenging to manage, especially in patients whose disease has already progressed on multiple lines of endocrine therapy,” she added.

    The study did not compare the efficacy of sacituzumab govitecan-hziy with trastuzumab deruxtecan (T-DXd; Enhertu), a HER2-targeted antibody-drug conjugate that is now approved for some HR-positive, HER2-negative breast cancers that express enough HER2 to be considered “HER2-low” or “HER2-ultralow.” T-DXd was not approved to treat HER2-low and -ultralow breast cancers in the chemotherapy naïve setting until after enrollment for the ASCENT-07 trial had closed.

    “The ASCENT-07 study design and choice of comparator was aligned with treatment guidelines for this line of treatment and disease setting at the time of study planning and conduct,” Jhaveri noted.

    The study was sponsored by Gilead Sciences. Jhaveri reports consulting and/or advisory board roles with Novartis, Pfizer, Genentech, Eisai Co., AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline Therapeutics, Gilead Sciences, Scorpion Therapeutics/Lilly, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck, Zymeworks, Halda Therapeutics, Arvinas, and RayzeBio. Jhaveri reports research funding to her institution from Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead Sciences, Puma Biotechnology, Merck, Scorpion Therapeutics, RayzeBio, Eisai Co., Bicycle Therapeutics, BridgeBio Oncology Therapeutics, and Blueprint Medicines.

    Download a photo of Jhaveri

    Continue Reading

  • Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial | AACR

    SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

    The results of this study were simultaneously published in the Journal of Clinical Oncology.

    HER2-positive breast cancer accounts for approximately 17% of all breast cancer cases and is associated with a five-year survival rate of less than 50% for patients with metastatic disease. Since 2012, the first-line treatment for HER2-positive metastatic breast cancer has remained largely unchanged, consisting of chemotherapy followed by maintenance therapy with dual anti-HER2 monoclonal antibodies, said Erika Hamilton, MD, director of Breast Cancer Research at Sarah Cannon Research Institute (SCRI) in Nashville. Currently, most patients experience disease progression within two years of starting treatment and often have to transition to chemotherapy. “The results of our study show that the addition of tucatinib to the standard of care represents an enhanced first-line maintenance therapy option for patients with HER2-positive metastatic breast cancer, providing an opportunity to prolong time to disease progression and time off chemotherapy,” said Hamilton, who presented this study.

    Tucatinib, a selective inhibitor of HER2, has previously shown efficacy in later lines of therapy, including in patients with brain metastases, according to the results from the HER2CLIMB study, Hamilton said. Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least one prior therapy. “The HER2CLIMB-05 trial was initiated to investigate the efficacy of tucatinib in a first-line maintenance setting in patients with HER2-positive metastatic breast cancer who completed chemotherapy-based induction therapy without disease progression,” she said. “We also wanted to assess whether targeting HER2 both intracellularly, with tucatinib, and extracellularly, with dual blockade with monoclonal antibodies, may potentially improve patient outcomes,” she added.

    The trial enrolled 654 patients with HER2-positive advanced breast cancer who had completed four to eight cycles of induction chemotherapy plus trastuzumab and pertuzumab, without disease progression. The patients were randomly assigned to receive either tucatinib or a placebo alongside continued trastuzumab and pertuzumab.

    At a median follow-up of 23 months, the patients who received tucatinib had a progression-free survival (PFS) of over two years—an improvement of 8.6 months compared with the patients in the control arm.

    Patients with hormone receptor (HR)-negative disease experienced a 44.6% reduction in risk of progression or death, with a 12.3-month improvement in median PFS. Those with HR-positive disease saw a 27.5% reduction in risk of progression or death and a 6.9-month improvement in median PFS.

    Among the 12.2% of patients with brain metastases at baseline, tucatinib nearly doubled the median central nervous system-PFS, which is the time taken for the cancer to progress to the brain or death from any cause—from 4.3 months to 8.5 months. “Central nervous system-PFS was a secondary endpoint and this finding is preliminary,” cautioned Hamilton, adding that 54% of the patients in the tucatinib arm remained on study treatment at the data cutoff of this analysis.

    These findings suggest that tucatinib may offer broad benefits across diverse patient subgroups, Hamilton said. She emphasized the importance of enhancing HER2 targeting during the maintenance phase, rather than waiting for disease progression. “Prolonging the maintenance phase allows patients to maintain disease control, while extending their time off chemotherapy,” she said. She noted that the results of the HER2CLIMB-05 trial, alongside recent data from the PATINA trial—where incorporating palbociclib (Ibrance) into the treatment regimen for HR-positive, HER2-positive metastatic breast cancer showed a 15-month improvement in PFS—support a shift toward more personalized first-line maintenance strategies for this patient population.

    A limitation of this study is the exclusive enrollment of patients who had not progressed after induction therapy, potentially introducing selection bias, Hamilton explained. Another limitation is that the differences in brain imaging frequency and the cessation of routine imaging after systemic progression may have affected the accuracy of central nervous system-PFS assessments.

    The study was funded by Seagen, which was acquired by Pfizer in December 2023. Hamilton holds consulting and advisory roles with Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis GmbH, Verascity Science, Theratechnologies, Accutar Biotech, Entos, Fosun Pharma, Gilead Sciences, Jaxx Pharmaceuticals, MphaR, Zentalis, Jefferies, and Tempus. She has received research funding from AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, StemcentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix/Inspirna, Novartis, Mersana, Millennium, TapImmune Inc./Marker Therapeutics, Lilly, Pfizer Inc., Tesaro, Boehringer Ingelheim, H3 Biomedicine/Eisai, Radius Health, Acerta Pharma, MacroGenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, NuCana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Sutro Biopharma, Zenith Epigenetics, Arvinas, Harpoon Therapeutics, Black Diamond Therapeutics, Orinove, Molecular Templates, Seagen, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Institute, Onconova Therapeutics, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, ImmunoGen, Plexxikon, Amgen, Akeso Biopharma, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Repertoire Immune Medicines, Treadwell Therapeutics, Jacobio Pharma, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque Therapeutics, BeiGene/BeOne Medicines, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology/Lilly, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, ProfoundBio, Cullinan Oncology/Cullinan Therapeutics, Bristol Myers Squibb, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, and Stemline Therapeutics.

    Download a photo of Hamilton

    Continue Reading